New drug aims to tame rare blood disorder and cut steroid dependence

NCT ID NCT04191304

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a drug called benralizumab can help control Hypereosinophilic Syndrome (HES), a rare disorder where high levels of white blood cells cause organ damage. About 134 patients aged 12 and older will receive either benralizumab or a placebo injection every 4 weeks, while continuing their standard HES medications. The main goal is to see if the drug can delay or prevent disease flares that typically require increased steroid doses or hospitalization.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

La Jolla, California, 92037, United States
Research Site

Atlanta, Georgia, 30324, United States
Research Site

Bethesda, Maryland, 20892, United States
Research Site

Ann Arbor, Michigan, 48105, United States
Research Site

Durham, North Carolina, 27705, United States
Research Site

Cleveland, Ohio, 44106, United States
Research Site

Columbus, Ohio, 43212, United States
Research Site

Salt Lake City, Utah, 84112, United States
Research Site

Rosario, 2000, Argentina
Research Site

Innsbruck, 6020, Austria
Research Site

Brussels, 1070, Belgium
Research Site

Edegem, 2650, Belgium
Research Site

Chengdu, 610041, China
Research Site

Tianjin, 300020, China
Research Site

Xiamen, 361015, China
Research Site

Zhengzhou, 450008, China
Research Site

København Ø, 2100, Denmark
Research Site

Lille, 59037, France
Research Site

Pessac, 33604, France
Research Site

Strasbourg, 67091, France
Research Site

Suresnes, 92151, France
Research Site

Toulouse, 31059, France
Research Site

Hanover, 30625, Germany
Research Site

Kirchheim, 73230, Germany
Research Site

Mannheim, 68167, Germany
Research Site

Ahmedabad, 380013, India
Research Site

Ajmer, 305001, India
Research Site

Delhi, 110029, India
Research Site

Haifa, 34362, Israel
Research Site

Holon, 58100, Israel
Research Site

Jerusalem, 91120, Israel
Research Site

Kfar Saba, 44218, Israel
Research Site

Petah Tikva, 49100, Israel
Research Site

Ramat Gan, 5265601, Israel
Research Site

Rehovot, 76100, Israel
Research Site

Tel Aviv, 64239, Israel
Research Site

Bologna, 40138, Italy
Research Site

Chiba, 260-0852, Japan
Research Site

Hamamatsu, 431-3192, Japan
Research Site

Ichikawa-shi, 272-8516, Japan
Research Site

Kawasaki-shi, 211-8510, Japan
Research Site

Nishinomiya-shi, 663-8501, Japan
Research Site

Osaka, 530-8480, Japan
Research Site

Sendai, 980-8574, Japan
Research Site

Rotterdam, 3015 GD, Netherlands
Research Site

Chęciny, 26-060, Poland
Research Site

Gdansk, 80-214, Poland
Research Site

Lodz, 90-153, Poland
Research Site

Seoul, 5505, South Korea
Research Site

Santander, 39010, Spain
Research Site

London, W2 1NY, United Kingdom

Conditions

Explore the condition pages connected to this study.

HYPEREOSINOPHILIC SYNDROME